Literature DB >> 18841881

Design, synthesis, and structure-affinity relationships of novel series of sialosides as CD22-specific inhibitors.

Hajjaj H M Abdu-Allah1, Taichi Tamanaka, Jie Yu, Lu Zhuoyuan, Magesh Sadagopan, Takahiro Adachi, Takeshi Tsubata, Soerge Kelm, Hideharu Ishida, Makoto Kiso.   

Abstract

Sialosides incorporating substituted amides or amines at 9-position of sialic acid moiety have been synthesized and evaluated as CD22 inhibitors. Several derivatives exhibited inhibitory potency in sub- to low micromolar range (e. g., 8o, 9d, 9g, and 9k showed IC 50 values 0.40, 0.47, 0.24, and 0.23 microM, respectively, for hCD22, while 8p, 8q, and 9f, showed IC 50 values 1.70, 2.90, and 4.10 microM, respectively, for mCD22). The most significant result was the strongly enhanced affinity of 9g and 9k containing 9-(2' or 4'-hydroxy-4-biphenyl) methylamino substituents (600-fold more potent for hCD22 than the corresponding 9-hydroxy derivative; 7a). Molecular modeling study was carried out to get some insights into the molecular basis of CD22 inhibition. To the best of our knowledge, this is the first systematic structure-affinity relationship study on inhibition of CD22.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18841881     DOI: 10.1021/jm8000696

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas.

Authors:  Cory D Rillahan; Matthew S Macauley; Erik Schwartz; Yuan He; Ryan McBride; Britni M Arlian; Janani Rangarajan; Valery V Fokin; James C Paulson
Journal:  Chem Sci       Date:  2014-06-01       Impact factor: 9.825

2.  CD22-antagonists with nanomolar potency: the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold.

Authors:  Hajjaj H M Abdu-Allah; Kozo Watanabe; Gladys C Completo; Magesh Sadagopan; Koji Hayashizaki; Chiaki Takaku; Taichi Tamanaka; Hiromu Takematsu; Yasunori Kozutsumi; James C Paulson; Takeshi Tsubata; Hiromune Ando; Hideharu Ishida; Makoto Kiso
Journal:  Bioorg Med Chem       Date:  2011-02-02       Impact factor: 3.641

Review 3.  Siglecs as targets for therapy in immune-cell-mediated disease.

Authors:  Mary K O'Reilly; James C Paulson
Journal:  Trends Pharmacol Sci       Date:  2009-04-07       Impact factor: 14.819

Review 4.  Synthesis of N-Glycolylneuraminic Acid (Neu5Gc) and Its Glycosides.

Authors:  Anoopjit Singh Kooner; Hai Yu; Xi Chen
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

5.  Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells.

Authors:  Chien-Hsing Chang; Yang Wang; Pankaj Gupta; David M Goldenberg
Journal:  MAbs       Date:  2015       Impact factor: 5.857

6.  CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.

Authors:  Naoko Matsubara; Akihiro Imamura; Tatsuya Yonemizu; Chizuru Akatsu; Hongrui Yang; Akiharu Ueki; Natsuki Watanabe; Hajjaj Abdu-Allah; Nobutaka Numoto; Hiromu Takematsu; Shinobu Kitazume; Thomas F Tedder; Jamey D Marth; Nobutoshi Ito; Hiromune Ando; Hideharu Ishida; Makoto Kiso; Takeshi Tsubata
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

Review 7.  Sialic acids as regulators of molecular and cellular interactions.

Authors:  Roland Schauer
Journal:  Curr Opin Struct Biol       Date:  2009-08-19       Impact factor: 6.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.